Emerging targets such as lymphocyte activation gene 3 (LAG-3) [60,61], T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) [62], and V-domain Ig suppressor of T cell activation (VISTA) [63] are being evaluated as potential inhibitors of anti-tumor immunity within the context of prostate tumors, either independently or in synergy with PD-1 signaling. Here, PDCD1 is linked to neoplasm.